Action Kineta - KA

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Dernier

0,5746

Prix Achat

0,582

Prix Vente

0,595

Volume échangé

0,00 Fourchette du Jour 0,00

0,3339 Plage de 52 semaines 3,16

Cap du marché

7,045M

Clôture Veille

0,5746

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

Actions en circulation

12 261 407

Rendement du Dividende

Ratio Cours sur Bénéfices

-1,64

Bénéfice par action (BPA)

-1,15

Chiffre d'affairess

5,44M

Bénéfice net

-14,1M

Kineta Inc is a clinical-stage biotechnology company with a mission to develop next generation immunotherapies that transform patients' lives. The company's lead asset is KVA12.1, a VISTA blocking immunotherapy. Kineta Inc is a clinical-stage biotechnology company with a mission to develop next generation immunotherapies that transform patients' lives. The company's lead asset is KVA12.1, a VISTA blocking immunotherapy.

Secteur

Pharmaceutical Preparations

Industrie

Pharmaceutical Preparations

Site Web

www.kinetabio.com

Siège social

Wilmington, Delaware, USA

Fondé

Kineta Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker KA. Le dernier cours de clôture d'Kineta était de US$0,57. Au cours de la dernière année, les actions de Kineta ont été négociées dans une fourchette de prix de US$ 0,3339 à US$ 3,16.

Kineta compte actuellement 12 261 407 actions en circulation. La capitalisation boursière d'Kineta est de US$7,05 million. Kineta a un ratio cours/bénéfice (ratio PE) de -1.64.

Form 8-K - Current report

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors

Kineta has completed enrollment in the monotherapy cohorts of the Phase 1 VISTA-101 clinical trial. The ongoing Phase 1 study is now enrolling patients into cohorts evaluating KVA12123 in...

Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024

SEATTLE, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (OTC Pink: KANT) , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address...

Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta’s VISTA blocking antibody Currently in Phase 1

TuHURA has extended their exclusivity and right of first offer pursuant to the terms of the agreement. Kineta and TuHURA are collaborating on the ongoing Phase 1/Phase 2 clinical trial in...

Form 8-K - Current report

Kineta, Inc Transitioning from Nasdaq to OTC Markets

Kineta will be trading under the symbol “KANT” on OTC Pink Kineta will continue to pursue strategic alternatives as previously announced TuHURA Biosciences has an exclusivity right and a right...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0.5746	0.5746	0.5746	0	0	CS
4	0	0	0.5746	0.5746	0.5746	0	0	CS
12	0	0	0.5746	0.5746	0.5746	0	0	CS
26	-0.1248	-17.843866171	0.6994	0.889	0.54	26739	0.66756566	CS
52	-2.5654	-81.7006369427	3.14	3.16	0.3339	292504	0.62625869	CS
156	-8.3054	-93.5292792793	8.88	9	0.3339	155466	0.9255106	CS
260	-8.3054	-93.5292792793	8.88	9	0.3339	155466	0.9255106	CS

KA - Frequently Asked Questions (FAQ)

What is the current Kineta share price?

The current share price of Kineta is US$ 0,5746

How many Kineta shares are in issue?

Kineta has 12 261 407 shares in issue

What is the market cap of Kineta?

The market capitalisation of Kineta is USD 7,05M

What is the 1 year trading range for Kineta share price?

Kineta has traded in the range of US$ 0,3339 to US$ 3,16 during the past year

What is the PE ratio of Kineta?

The price to earnings ratio of Kineta is -1,64

What is the cash to sales ratio of Kineta?

The cash to sales ratio of Kineta is 4,26

What is the reporting currency for Kineta?

Kineta reports financial results in USD

What is the latest annual turnover for Kineta?

The latest annual turnover of Kineta is USD 5,44M

What is the latest annual profit for Kineta?

The latest annual profit of Kineta is USD -14,1M

What is the registered address of Kineta?

The registered address for Kineta is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808

What is the Kineta website address?

The website address for Kineta is www.kinetabio.com

Which industry sector does Kineta operate in?

Kineta operates in the PHARMACEUTICAL PREPARATIONS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
PHIOPhio Pharmaceuticals Corporation	US$ 7,18 (324,85%)	265,54M
SLRXSalarius Pharmaceuticals Inc	US$ 4,005 (155,91%)	113,72M
ATPCAgape ATP Corporation	US$ 2,03 (61,11%)	82,3M
VRMEVerifyMe Inc	US$ 3,9501 (54,91%)	53,69M
XXII22nd Century Group Inc	US$ 6,798 (39,02%)	22,56M
EHGOEshallgo Inc	US$ 1,29 (-60,55%)	5,61M
CMTLComtech Telecommunications Corporation	US$ 2,28 (-44,79%)	3,8M
HUBCWHub Cyber Security Ltd	US$ 0,0176 (-41,33%)	265,23k
SVMHSRIVARU Holding Ltd	US$ 0,0364 (-41,10%)	162,57M
GRNQGreenpro Capital Corporation	US$ 1,12 (-40,74%)	2,58M
GCTKGlucoTrack Inc	US$ 0,136701 (16,84%)	645,39M
PHIOPhio Pharmaceuticals Corporation	US$ 7,18 (324,85%)	265,54M
BHATBlue Hat Interactive Entertainment Technology	US$ 0,0632 (-28,26%)	179,41M
SVMHSRIVARU Holding Ltd	US$ 0,0364 (-41,10%)	162,57M
NVDANVIDIA Corporation	US$ 132,1893 (-2,74%)	160,47M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Kineta Inc (KA) Cours

Kineta Inc (KA)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

À propos de Kineta Inc

KA Dernières nouvelles

KA - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application